After treatment with teclistamab, she had significant improvement in all disease domains at 12-week follow-up with a decrease in her Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) and Disease Activity Score 28 for Rheumatoid Arthritis with CRP (DAS28-CRP), as well as an increase in her lung diffusion capacity and strength by MMT-8. Here, CRP is linked to rheumatoid arthritis.